EE200300216A - Radiofarmatseutilised ained Alzheimeri tõve diagnoosimiseks - Google Patents
Radiofarmatseutilised ained Alzheimeri tõve diagnoosimiseksInfo
- Publication number
- EE200300216A EE200300216A EEP200300216A EEP200300216A EE200300216A EE 200300216 A EE200300216 A EE 200300216A EE P200300216 A EEP200300216 A EE P200300216A EE P200300216 A EEP200300216 A EE P200300216A EE 200300216 A EE200300216 A EE 200300216A
- Authority
- EE
- Estonia
- Prior art keywords
- radiopharmaceuticals
- alzheimer
- diagnosis
- disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24629900P | 2000-11-06 | 2000-11-06 | |
| PCT/EP2001/012607 WO2002036581A1 (en) | 2000-11-06 | 2001-11-01 | Radiopharmaceuticals for diagnosing alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EE200300216A true EE200300216A (et) | 2003-08-15 |
Family
ID=22930075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EEP200300216A EE200300216A (et) | 2000-11-06 | 2001-11-01 | Radiofarmatseutilised ained Alzheimeri tõve diagnoosimiseks |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US6676926B2 (et) |
| EP (1) | EP1332138B1 (et) |
| JP (1) | JP4234425B2 (et) |
| KR (1) | KR20030045167A (et) |
| CN (1) | CN1473158A (et) |
| AR (1) | AR035366A1 (et) |
| AT (1) | ATE314354T1 (et) |
| AU (2) | AU1403402A (et) |
| BG (1) | BG107762A (et) |
| BR (1) | BR0115150A (et) |
| CA (1) | CA2424598A1 (et) |
| DE (1) | DE60116365T2 (et) |
| EA (1) | EA006199B1 (et) |
| EE (1) | EE200300216A (et) |
| HR (1) | HRP20030459A2 (et) |
| HU (1) | HUP0301710A3 (et) |
| IL (1) | IL155191A0 (et) |
| JO (1) | JO2207B1 (et) |
| MX (1) | MXPA03003759A (et) |
| NO (1) | NO20032007L (et) |
| NZ (1) | NZ525303A (et) |
| PE (1) | PE20020531A1 (et) |
| PL (1) | PL361631A1 (et) |
| SK (1) | SK287495B6 (et) |
| TW (1) | TWI238820B (et) |
| UY (1) | UY27003A1 (et) |
| WO (1) | WO2002036581A1 (et) |
| YU (1) | YU33203A (et) |
| ZA (1) | ZA200304409B (et) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY27003A1 (es) * | 2000-11-06 | 2002-07-31 | Schering Ag | Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer |
| OA12670A (en) | 2001-10-22 | 2006-06-20 | Pfizer Prod Inc | Piperazine derivatives with ccr1 receptor antagonist activity. |
| EP1465869B1 (en) | 2001-12-21 | 2013-05-15 | Exelixis Patent Company LLC | Modulators of lxr |
| US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
| DK1620373T3 (da) * | 2003-05-07 | 2008-07-28 | Bayer Schering Pharma Ag | Apparat og fremgangsmåde til nucleofil fluorering |
| WO2005082425A1 (en) * | 2004-02-24 | 2005-09-09 | The General Hospital Corporation | Catalytic radiofluorination |
| US8257680B1 (en) | 2004-02-24 | 2012-09-04 | The General Hospital Corporation | Catalytic radiofluorination |
| US9017724B2 (en) | 2004-02-24 | 2015-04-28 | The General Hospital Corporation | Catalytic radiofluorination |
| GB0409236D0 (en) * | 2004-04-26 | 2004-05-26 | Novartis Ag | Organic compounds |
| US7833513B2 (en) | 2004-12-03 | 2010-11-16 | Rhode Island Hospital | Treatment of Alzheimer's Disease |
| KR100778888B1 (ko) * | 2005-11-29 | 2007-11-28 | 재단법인서울대학교산학협력재단 | 베타아밀로이드 펩타이드 플라크의 영상화를 위한벤질리덴아닐린 계열의 유도체 및 그의 방사성 동위원소표지화합물 |
| KR101922515B1 (ko) | 2006-09-08 | 2019-02-20 | 로드아일랜드하스피틀 | 알코올 유발성 간 질환의 치료, 예방 및 역행 |
| AU2007292883B2 (en) | 2006-09-08 | 2013-09-05 | Rhode Island Hospital | Treatment, prevention, and reversal of alcohol-induced brain disease |
| JP5562036B2 (ja) * | 2006-12-21 | 2014-07-30 | ハマースミス・イメイネット・リミテッド | 放射性標識方法 |
| GB0625523D0 (en) | 2006-12-21 | 2007-01-31 | Ge Healthcare Ltd | In vivo imaging agents |
| JP2011502966A (ja) * | 2007-10-31 | 2011-01-27 | アルセレス ファーマシューティカルズ， インコーポレイテッド | ドーパミントランスポーターレベルを評価することによるレビー小体型認知症の診断およびレビー小体型認知症の処置のモニタリングのための方法 |
| US8450466B2 (en) | 2008-03-21 | 2013-05-28 | The General Hosptial Corporation | Compounds and compositions for the detection and treatment of Alzheimer's disease and related disorders |
| EP2161256A1 (en) * | 2008-09-08 | 2010-03-10 | Atomic Energy Council - Institute of Nuclear Energy Research | Compound containing carboxylate ester and N2S2 ligand bi-functional groups and manufacturing method thereof |
| EP2163541A1 (en) * | 2008-09-12 | 2010-03-17 | Bayer Schering Pharma Aktiengesellschaft | Piperazine derivatives for binding and imaging amyloid plaques and their use |
| WO2011041470A2 (en) * | 2009-09-30 | 2011-04-07 | Mallinckrodt Inc. | Sustained-release opiate and opiate derivative compositions |
| TW201201846A (en) * | 2010-02-08 | 2012-01-16 | Bayer Schering Pharma Ag | Iodo precursor for a PET imaging agent of amyloid plaques |
| WO2011110511A1 (en) * | 2010-03-11 | 2011-09-15 | Bayer Pharma Aktiengesellschaft | Spect imaging agents of amyloid plaques |
| WO2012159107A1 (en) | 2011-05-19 | 2012-11-22 | Rhode Island Hospital | Inhibition of renal fibrosis |
| ES2973048T3 (es) | 2013-12-27 | 2024-06-18 | Univ Nat Corp Tokyo Medical & Dental | Método para el diagnóstico de la enfermedad de Alzheimer y la degeneración lobar frontotemporal, agente de diagnóstico, agente terapéutico y método de cribado ("screening") para dichos agentes |
| MX382156B (es) | 2015-08-28 | 2025-03-13 | Chdi Foundation Inc | Sondas para formar imagenes de proteina de huntingtina. |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0576611A4 (en) | 1991-03-13 | 1996-01-24 | Univ Minnesota | Radiopharmaceutical agents for the detection of alzheimer's disease |
| EP0524146A1 (de) | 1991-07-19 | 1993-01-20 | Ciba-Geigy Ag | Aminosubstituierte Piperazinderivate |
| GB9413772D0 (en) | 1994-07-08 | 1994-08-24 | Wyeth John & Brother Ltd | 5-HT1A ligands |
| US5919797A (en) * | 1996-04-24 | 1999-07-06 | Emory University | Halogenated naphthyl methoxy piperidines for mapping serotonin transporter sites |
| EP0920306A2 (en) | 1996-07-12 | 1999-06-09 | Leukosite, Inc. | Chemokine receptor antagonists and methods of use therefor |
| FR2758328B1 (fr) | 1997-01-15 | 1999-04-02 | Pf Medicament | Nouvelles amines aromatiques derivees d'amines cycliques utiles comme medicaments |
| US6207665B1 (en) * | 1997-06-12 | 2001-03-27 | Schering Aktiengesellschaft | Piperazine derivatives and their use as anti-inflammatory agents |
| AUPP278498A0 (en) * | 1998-04-03 | 1998-04-30 | Australian Nuclear Science & Technology Organisation | Peripheral benzodiazepine receptor binding agents |
| US6288083B1 (en) | 1998-09-04 | 2001-09-11 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
| AUPP818099A0 (en) | 1999-01-14 | 1999-02-11 | Fujisawa Pharmaceutical Co., Ltd. | New n-containing heterocyclic compounds |
| EE200100502A (et) | 1999-03-26 | 2002-12-16 | Astrazeneca Ab | Ühendid |
| UY27003A1 (es) * | 2000-11-06 | 2002-07-31 | Schering Ag | Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer |
-
2001
- 2001-10-31 UY UY27003A patent/UY27003A1/es not_active Application Discontinuation
- 2001-11-01 PL PL01361631A patent/PL361631A1/xx not_active Application Discontinuation
- 2001-11-01 IL IL15519101A patent/IL155191A0/xx unknown
- 2001-11-01 EE EEP200300216A patent/EE200300216A/et unknown
- 2001-11-01 EP EP01982450A patent/EP1332138B1/en not_active Expired - Lifetime
- 2001-11-01 YU YU33203A patent/YU33203A/sh unknown
- 2001-11-01 JP JP2002539340A patent/JP4234425B2/ja not_active Expired - Fee Related
- 2001-11-01 SK SK547-2003A patent/SK287495B6/sk not_active IP Right Cessation
- 2001-11-01 AT AT01982450T patent/ATE314354T1/de not_active IP Right Cessation
- 2001-11-01 EA EA200300507A patent/EA006199B1/ru not_active IP Right Cessation
- 2001-11-01 AU AU1403402A patent/AU1403402A/xx active Pending
- 2001-11-01 DE DE60116365T patent/DE60116365T2/de not_active Expired - Lifetime
- 2001-11-01 HU HU0301710A patent/HUP0301710A3/hu unknown
- 2001-11-01 CA CA002424598A patent/CA2424598A1/en not_active Abandoned
- 2001-11-01 BR BR0115150-9A patent/BR0115150A/pt not_active IP Right Cessation
- 2001-11-01 HR HR20030459A patent/HRP20030459A2/hr not_active Application Discontinuation
- 2001-11-01 MX MXPA03003759A patent/MXPA03003759A/es unknown
- 2001-11-01 NZ NZ525303A patent/NZ525303A/en unknown
- 2001-11-01 KR KR10-2003-7006187A patent/KR20030045167A/ko not_active Withdrawn
- 2001-11-01 AU AU2002214034A patent/AU2002214034B2/en not_active Ceased
- 2001-11-01 CN CNA01818409XA patent/CN1473158A/zh active Pending
- 2001-11-01 WO PCT/EP2001/012607 patent/WO2002036581A1/en not_active Ceased
- 2001-11-02 AR ARP010105127A patent/AR035366A1/es unknown
- 2001-11-05 JO JO2001178A patent/JO2207B1/en active
- 2001-11-05 PE PE2001001092A patent/PE20020531A1/es not_active Application Discontinuation
- 2001-11-06 TW TW090127552A patent/TWI238820B/zh not_active IP Right Cessation
- 2001-11-06 US US09/985,938 patent/US6676926B2/en not_active Expired - Fee Related
-
2003
- 2003-04-25 BG BG107762A patent/BG107762A/xx unknown
- 2003-05-05 NO NO20032007A patent/NO20032007L/no unknown
- 2003-06-05 ZA ZA200304409A patent/ZA200304409B/en unknown
- 2003-07-25 US US10/626,725 patent/US6872381B1/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EE200300216A (et) | Radiofarmatseutilised ained Alzheimeri tõve diagnoosimiseks | |
| EE200200716A (et) | Ühendid Alzheimeri tõve käitluseks | |
| PT2264018E (pt) | Derivados de tioflavina para uso no diagnóstico da doença de alzheimer | |
| IL224393B (en) | Compositions for treatment of huntington's disease | |
| NO20054640D0 (no) | Fremgangsmater for behandling av Parkinsons sykdom | |
| DK1392287T3 (da) | Anvendelse af substituerede azetidinonderivater i behandlingen af Alzheimers sygdom | |
| AU2003206413A8 (en) | Substituted amino carboxamides for the treatment of alzheimer's disease | |
| DK1443955T3 (da) | PDGF-BB til behandling af Parkinsons sygdom | |
| NO20001869D0 (no) | Fremgangsmõte for behandling av Alzheimerssykdom | |
| AU2002315131A1 (en) | Aminediols as agents for the treatment of alzheimer's disease | |
| ITMI20010985A0 (it) | Farmaci per il morbo di alzheimer | |
| AU2001236592A1 (en) | Methods for diagnosis of alzheimer's disease | |
| AU2003303141A8 (en) | Hydroxypropyl amides for the treatment of alzheimer's disease | |
| FR2845267B1 (fr) | Kit cutane de diagnostic de l'atopie | |
| IL175004A0 (en) | Quick test for the diagnosis of alzheimer's disease | |
| EP1181550A4 (en) | METHODS OF IDENTIFYING COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
| AU6584401A (en) | A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease | |
| AU2003236714A8 (en) | Diagnosis of alzheimer's disease based on the habeta42:habeta40 ratio | |
| IL172690A0 (en) | Methods for the diagnosis and prognosis of alzheimer's disease | |
| AU2003299101A1 (en) | Compounds for the treatment of alzheimer's disease | |
| EP1693671A4 (en) | METHOD FOR DIAGNOSING ALZHEIMER'S DISEASE | |
| AU2002364885A8 (en) | Alzheimer's disease model | |
| GB0012123D0 (en) | Alzheimer's disease assay | |
| GB0127473D0 (en) | Compounds for imaging alzheimer's disease | |
| GB0217713D0 (en) | Compounds for imaging alzheimer's disease |